Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, announced that CARB-X, a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, will provide up to $3.6 million in additional non-dilutive funding to […]
Concerto Biosciences®, a clinical-stage biotech company developing microbial products for therapeutics and consumer markets, today announced positive topline results from its first-in-human Phase 1b clinical trial evaluating ENS-002, a topical three-strain live biotherapeutic product for […]
Researchers at the Icahn School of Medicine at Mount Sinai and their collaborators have developed a new technology to track beneficial bacteria after fecal microbiota transplants (FMT). The approach provides a detailed view of how […]
Hundreds of new viruses living inside bacteria within our gut have been discovered in an international study led by Professor Jeremy J. Barr from Monash University’s School of Biological Sciences and Associate Professor Sam Forster […]
Founded in 2021, Phagos is ushering in a new era in the fight against bacterial disease with bacteriophages, a powerful alternative to antibiotics. Thanks to an unprecedented regulatory breakthrough and a discovery platform combining microbiology […]
A pioneering research network to unlock the link between gut, immune and brain health has taken its first steps at a launch event on September 22 in Southampton. Researchers and stakeholders from across the UK […]